This exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area
of cancer supportive care across multiple global territories
Helsinn Group Signs Exclusive Agreement with Mundipharma for Distribution and Licence of Anamorelin in China, Hong Kong and Macao
Linkedin